Results 131 to 140 of about 31,918 (237)

NEUTROPENIA FEBRIL EN PEDIATRIA Febrile Neutropenia in Pedriatrics

Infectio, 2008
La neutropenia febril es una condición frecuente en los pacientes pediátricos con cáncer. En el momento en que se hace este diagnóstico, el médico debe conducir una entrevista y un examen físico rigurosos, obtener cultivos e iniciar antibióticos para ...
Pio Lopez, Eduardo Lopez
doaj  

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population [PDF]

, 2022
Ching‐Yu Wang, Haesuk Park, Coy D. Heldermon, Scott Martin Vouri, Joshua D. Brown   +4 more
openalex   +1 more source

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

British Journal of Haematology, Volume 208, Issue 1, Page 149-158, January 2026.
Summary A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 ...
Swetha Kambhampati Thiruvengadam, Leslie L. Popplewell, Alex F. Herrera, Matthew Mei, Liana Nikolaenko, Xiaofang Zuo, Shen Yin, Mingzhu Zhou, Yong Mun, Mei Wu, Michael C. Wei, Lihua E. Budde   +11 more
wiley   +1 more source

The importance of assessing the fitness of older patients with newly diagnosed diffuse large B‐cell lymphoma and classic Hodgkin lymphoma

British Journal of Haematology, Volume 208, Issue 1, Page 58-66, January 2026.
Summary Several tools have been developed to provide prognostic indicators that are more accurate than chronological age alone because choosing the best treatment for older lymphoma patients is challenging. For older patients with diffuse large B‐cell lymphoma (DLBCL), one of these prognostic indicators is patient fitness; its definition has been ...
Vittorio Ruggero Zilioli, Alessandra Tucci, Michele Spina, Francesco Merli, Annalisa Arcari, on behalf of the Elderly Lymphoma Committee of the Fondazione Italiana Linfomi   +5 more
wiley   +1 more source

Search for novel biomarkers of febrile neutropenia in hematological patients: an overview. [PDF]

Clin Exp Med
Jantunen E, Hämäläinen S, Pulkki K, Juutilainen A.   +3 more
europepmc   +1 more source

In-hospital mortality prognostication for cancer patients with febrile neutropenia. [PDF]

Commun Med (Lond)
Tahir A, Hassan M, Farooq A, Ashfaq S, Ayub M, Hameed I, Sheikh AZ, Ahad A, Azad J, Ahmed U, Aleem A, Masood A, Asghar K, Khan AW, Chaudhary SU.   +14 more
europepmc   +1 more source

Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Pre‐therapeutic UGT1A1 genotyping is increasingly performed in patients receiving irinotecan, as its active metabolite SN‐38 is primarily cleared through UGT1A1‐mediated glucuronidation. Patients with the UGT1A1*28/*28 genotype exhibit reduced UGT1A1 activity, leading to increased SN‐38 exposure and a higher risk of adverse events such as ...
Tessa Goedhart, Henk‐Jan Guchelaar
wiley   +1 more source

Evaluation of malnutrition in patients with febrile neutropenia. [PDF]

North Clin Istanb
Akbas ES, Basak SU, Sevim E.
europepmc   +1 more source

Role of Frailty in Assessing Eligibility for CAR T‐Cell Therapy in Haematology

European Journal of Haematology, Volume 116, Issue 1, Page 4-13, January 2026.
ABSTRACT Background and Objectives Frailty is a key consideration in determining whether a patient is robust enough for CAR T‐cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T‐cell therapy ...
Jennifer Clesham, Joan McGrory, Aoife Bannon, Deirbhle Cox, Maura Dowling   +4 more
wiley   +1 more source

Asymptomatic Candiduria due to Candida inconspicua in a Patient With Hematologic Malignancy

Case Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Candida inconspicua is an uncommon opportunistic yeast, increasingly reported in immunocompromised patients. We describe a case of asymptomatic Candiduria caused by C. inconspicua in a 43‐year‐old woman with Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukemia undergoing chemotherapy.
Andrés Soto, Javier Tinoco-Cahuana, Paulo Charpentier-Videla, Edgardo Rojas-Mancilla, Diego Macias-Cofre, Daniela Caceres-Canales, Cecilia Morales-Gonzalez, Lissette Guajardo-Quileñan, Jose Luis Briones-Martinez, Esteban Mejias-Escobar, Carolina Selman-Bravo, Francisca Sanchez-Jorquera, Dawei Cui   +12 more
wiley   +1 more source